- Reuters
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 2/20/2026 | $185.00 | Equal Weight | Barclays | |
| 1/20/2026 | $335.00 | Outperform → Mkt Perform | Bernstein | |
| 1/7/2026 | $380.00 | Buy | UBS | |
| 12/5/2025 | Hold → Buy | Erste Group | ||
| 11/24/2025 | $318.00 | Hold | Truist | |
| 11/13/2025 | $385.00 | Sector Outperform | Scotiabank | |
| 9/3/2025 | Mkt Perform | Raymond James | ||
| 5/20/2025 | $288.00 | Neutral | Guggenheim |
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN" or "Horizon"), an affiliate of Monroe Capital, announced today that it plans to release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, March 4, 2026, at 9:00 a.m. ET. The conference call will feature remarks by Mike Balkin, Chief Executive Officer, Paul Seitz, Senior Vice President and Chief Investment Officer, and Dan Trolio, Executive Vice President and Chief Financial Officer. To participate in the call, please dial (877) 407-9716 (domestic) or (201) 493-6779 (interna
The atopic dermatitis market is expected to grow, driven by the extensive market penetration of approved therapies for moderate-to-severe atopic dermatitis and the entry of new therapies such as OX40 inhibitor (Rocatinlimab [KHK4083/AMG451]), OX40L inhibitor (Amlitelimab [KY1005]), PDE4 inhibitor (Orismilast), TSLP inhibitor (Bosakitug [BSI-045B]), IL-22RA1 blocker (Temtokibart [LP0145; LEO 138559]), IL-4Rα blocker (Rademikibart [CBP-201]), and others.LAS VEGAS, Feb. 16, 2026 /PRNewswire/ -- Recently published Atopic Dermatitis Market Insights report includes a comprehensive understanding of current treatment practices, atopic dermatitis emerging drugs, market share of individual therapies,
THOUSAND OAKS, Calif., Feb. 13, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding p
Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Submission status for AMGEN INC's drug PAVBLU (ORIG-1) with active ingredient AFLIBERCEPT has changed to 'Approval' on 08/23/2024. Application Category: BLA, Application Number: 761298, Application Classification:
Submission status for AMGEN INC's drug REPATHA (SUPPL-43) with active ingredient EVOLOCUMAB has changed to 'Approval' on 08/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:
Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00
Bernstein downgraded Amgen from Outperform to Mkt Perform and set a new price target of $335.00
UBS resumed coverage of Amgen with a rating of Buy and set a new price target of $380.00
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
8-K - AMGEN INC (0000318154) (Filer)
FWP - AMGEN INC (0000318154) (Subject)
424B3 - AMGEN INC (0000318154) (Filer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or "HRZN") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital and private equity backed and publicly traded companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that it has appointed Paul Seitz as its new Chief Investment Officer. Concurrently, Daniel Devorsetz has stepped down as Chief Operating Officer and Chief Investment Officer, but will remain involved with the Company through September 2025. "We are thrilled to welcome Paul as our new Chi
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN" or "Horizon"), an affiliate of Monroe Capital, announced today that it plans to release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, March 4, 2026, at 9:00 a.m. ET. The conference call will feature remarks by Mike Balkin, Chief Executive Officer, Paul Seitz, Senior Vice President and Chief Investment Officer, and Dan Trolio, Executive Vice President and Chief Financial Officer. To participate in the call, please dial (877) 407-9716 (domestic) or (201) 493-6779 (interna
THOUSAND OAKS, Calif., Feb. 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024. "Amgen delivered strong performance in 2025, with double-digit growth in revenues and earnings per share. We enter 2026 with momentum across a broad portfolio of medicines and a clear path towards advancing innovative therapies to deliver sustained long-term growth," said Robert A. Bradway, chairman and chief executive officer. Key results include: For the fourth quarter, total revenues increased 9% to $9.9 billion in comparison to the fourth quarter of 2024.Product sales grew 7%, driven by 10% volume gro
THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public. The webcast, as with other sel
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13D - AMGEN INC (0000318154) (Filed by)